Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

Abstract

To the Editor: The trial by Wechsler et al. (March 7 issue)¹ was designed to evaluate whether benralizumab is noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The noninferiority margin was defined as an absolute difference of no more than −25 percentage points between the benralizumab and mepolizumab groups in the percentage of patients with remission. Although EGPA is a rare disease, no clear clinical rationale was provided for this large noninferiority margin. The adjusted percentage of patients with remission at weeks 36 and 48 was 59% with benralizumab . . .